Structure–Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions
作者:Anna Jirkovská、Galina Karabanovich、Jan Kubeš、Veronika Skalická、Iuliia Melnikova、Jan Korábečný、Tomáš Kučera、Eduard Jirkovský、Lucie Nováková、Hana Bavlovič Piskáčková、Josef Škoda、Martin Štěrba、Caroline A. Austin、Tomáš Šimůnek、Jaroslav Roh
DOI:10.1021/acs.jmedchem.0c02157
日期:2021.4.8
interaction with TOP2B in cardiomyocytes, but was independent of their iron chelation ability. Very tight structure–activity relationships were demonstrated on stereoisomeric forms of 4,4′-(butane-2,3-diyl)bis(piperazine-2,6-dione). In contrast to its rac-form 12, meso-derivative 11 (ICRF-193) showed a favorable binding mode to topoisomerase II in silico, inhibited and depleted TOP2B in cardiomyocytes more efficiently
右雷佐生 (ICRF-187) 是唯一临床批准的抗蒽环类药物引起的心脏毒性的药物,其心脏保护活性传统上归因于其铁螯合代谢物。然而,最近的实验证据表明,右雷佐生抑制和/或消耗拓扑异构酶 IIβ (TOP2B) 可能具有心脏保护作用。因此,我们评估了一系列右雷佐生类似物,发现它们的心脏保护活性与其与心肌细胞中TOP2B的相互作用密切相关,但与其铁螯合能力无关。 4,4'-(丁烷-2,3-二基)双(哌嗪-2,6-二酮)的立体异构形式证明了非常紧密的结构-活性关系。与其外消旋形式12相比,内消旋衍生物11 (ICRF-193)在计算机模拟中显示出与拓扑异构酶 II 良好的结合模式,比右雷佐生更有效地抑制和耗尽心肌细胞中的 TOP2B,并显示出最高的心脏保护效率。重要的是,观察到的 ICRF-193 心脏保护作用不会干扰蒽环类药物的抗增殖活性。因此,本研究将 ICRF-193 确定为开发有效心脏保护剂的新先导化合物。